Innova Biosciences Introduces Range of Conjugated Antibodies

08:18 EDT 10 Aug 2015 | BioPortfolio

Range of antibodies to cardiac biomarkers conjugated to enzymes, fluorescent dyes and nanoparticles

Cambridge, UK, 10 August 2015: Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, announced today the launch of a range of conjugated antibodies. The unique range leverages Innova’s Lightning-Link® and InnovaCoat® bioconjugation technologies, to provide customers with antibodies conjugated to an extensive range of enzymes, fluorescent dyes and colloidal gold, for improved flexibility in experimental design.

The new range comprises 200 antibodies to nearly 30 different cardiac biomarkers, each available directly conjugated to 24 different enzymes, fluorescent dyes or nanoparticles. Innova intends to expand the range into other key research areas in the near future, catering to an increasingly wide scientific audience.

In conjunction with the new range, Innova has launched a new corporate website, to provide customers with easier online ordering facilities, as well as access to a range of resources and support materials. The website also features an Antibody Conjugate Generator tool, which enables customers ordering from the new conjugated antibodies range to select any desired cardiac marker, antibody clone and label.

The online Conjugate Generator provides Innova’s customers with unprecedented flexibility, speed and conjugation possibilities, enabling highly tailored reagents to be created at a fraction of the cost of a custom conjugation project.

Dr Nick Gee, CEO at Innova, said: "This new range represents a progression for Innova from our range of bioconjugation kits. For the first time we are offering antibodies, capitalising on our conjugation technologies to create a powerful new tool for researchers.”

For more information about the new conjugated antibody range please visit

Image: Antibody conjugates

About Innova Biosciences Limited

Innova Biosciences is a rapidly growing, dynamic business based in Cambridge at the heart of the UK’s leading innovation centre. At the core of Innova's business are bioconjugation and nanoparticle technologies including Lightning-Link®, InnovaCoat® and Thunder-Link® brands, which provide easy to use kits which overcome many of the problems associated with traditional bioconjugation. Innova’s products are suitable for both small scale R&D applications and large scale manufacturing.

For more information, please see

Media contacts Katie Odgaard, Zyme Communications Email: Phone: +44 (0)7787 502 947 At Innova Biosciences Dr Andy Lane, Executive Director Email: Phone: +44 (0) 1223 496 170 NEXT ARTICLE

More From BioPortfolio on "Innova Biosciences Introduces Range of Conjugated Antibodies"

Quick Search


Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cloning in biology is the process of producing similar populations of genetically identical individuals that occurs in nature when organisms such as bacteria, insects or plants reproduce asexually. Cloning in biotechnology refers to processes used to cre...